Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies

Area of Science:

• Neuroscience
• Microbiology
• Genetics

Background:

• Major depressive disorder (MDD) is a leading cause of global disability, influenced by environmental factors like diet and microbes.
• Depression pathogenesis involves complex interactions between genetics, epigenetics, and the immune system.
• Gut microbiome alterations impact stress responses and social behavior via immune cell maturation and neurogenesis.

Purpose of the Study:

• To explore the role of a leaky gut in MDD development through microbiota-derived metabolites and epigenetic effects.
• To examine how gut microbiome composition changes contribute to MDD via epigenetic alterations.
• To discuss therapeutic strategies modulating the gut microbiome and epigenetic landscape for MDD.

Main Methods:

• Review of current research on gut microbiota, metabolites, and their epigenetic influence on depression.
• Analysis of how specific metabolites (e.g., butyrate), probiotics, diet, and drugs affect epigenetic modifications.
• Discussion of fecal microbiota transplantation (FMT) as a potential therapeutic approach.

Main Results:

• Gut microbiota-derived metabolites can exert epigenetic effects, influencing stress-related responses and neurogenesis.
• Altering gut microbiome composition is linked to epigenetic changes contributing to MDD.
• Interventions like probiotics, specific diets, and FMT show potential in alleviating depressive behaviors by modulating epigenetics.

Conclusions:

• A leaky gut and associated microbial metabolite changes may contribute to MDD pathogenesis via epigenetic pathways.
• Modulating the gut microbiome and its epigenetic effects presents a promising therapeutic avenue for MDD.
• Challenges and opportunities exist in developing microbiome-related epigenetic therapies for depression.